Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatIschaemia-reperfusionRenalWistarMalen = 60 rats in five groups1.5 g/kg/day low dose and 3.0 g/kg/day high doseTreatment for one week before ischaemia-reperfusion surgery
Model: Renal ischaemia-reperfusion injury induced surgically, assessed at 24 and 72 hours
Shenhua Tablet, most markedly at the high dose, reduced renal functional and pathological injury and downregulated toll-like receptor 2 and 4 and myeloid differentiation factor 88 signalling with associated falls in tumour necrosis factor alpha and interleukin-6.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.